A criança é o pai do homem: novos desafios para a área de saúde da criança

Moreira, Maria Elisabeth Lopes; Goldani, Marcelo Zubarán

doi:10.1590/s1413-81232010000200002

Cited by 42 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most newborns with life-threatening conditions survived the neonatal period, but they will likely require greater attention from health services and families due to the chronic character of some of their conditions, thus contributing to a new childhood morbidity profile 37 . …”

Section: Discussionmentioning

confidence: 99%

Neonatal near miss and mortality: factors associated with life-threatening conditions in newborns at six public maternity hospitals in Southeast Brazil

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Neonatal near miss and mortality: factors associated with life-threatening conditions in newborns at six public maternity hospitals in Southeast Brazil

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Approximately two-thirds of the drugs used in pediatric clinical practice do not have enough evidence about dosages, safety, and efficacy for each phase of development 13 . Children compose a substantial proportion of the population of patients with VL, particularly in New World VL.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil

Borges

Pranchevicius

Noronha

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Despite their high toxicity, antimonials and amphotericin B deoxycholate are commonly used for treating visceral leishmaniasis (VL). Few studies showing conflictive data about their efficacy and adverse events in pediatric population are available. This study aimed to evaluate efficacy and safety of amphotericin B deoxycholate vs. that of N-methylglucamine antimoniate in treating pediatric VL in Brazil. Methods: This was a randomized, open-label, 2-arm and controlled pilot clinical trial. Treatment naïve children and adolescents with VL without signs of severe illness were treated with N-methylglucamine antimoniate (20mg/ kg/day for 20 days) or amphotericin B deoxycholate (1mg/kg/day for 14 days). All patients were diagnosed with positive direct examination and/or positive PCR for Leishmania spp. performed in bone marrow samples. The primary efficacy end-point was VL cure determined after 180 days of completion of treatment. The analysis was performed using intention-to-treat (ITT) and per protocol (PP) analyses. Results: In total, 101 volunteers were assessed. Efficacy was similar for both groups. The antimonial (n=51) and amphotericin B groups (n=50) had a cure rate of 94.1% and 100%, and 94% and 97.9% according to ITT and PP analyses, respectively. All patients reported adverse events (AE). Serious AE incidence was similar in both groups. Five individuals were excluded from the study because of severe adverse events. Conclusions: N-methylglucamine antimoniate and amphotericin B deoxycholate have similar efficacy and adverse events rate in pediatric patients with VL.

show abstract

“…There has been a demographic and epidemiological transition in pediatric care which can be characterised by the increase of chronic cases of overweight patients, infant obesity, reducing malnutrition and a reduction in infant mortality rates between the ages of two months and five years, actions aimed at increasing breast feeding, access to pre natal care, treating pneumonia, diarrhoea and the administration of vaccines (Moreira & Goldani, 2010). This has had a profound impact on hospital care and point towards the construction of a new model of healthcare which should be expanded to included the prevention and treatment of infant diseases to guarantee the health of individuals so that they can grow and develop.…”

Section: Chronic Disease In Childhoodmentioning

confidence: 99%

“…This has had a profound impact on hospital care and point towards the construction of a new model of healthcare which should be expanded to included the prevention and treatment of infant diseases to guarantee the health of individuals so that they can grow and develop. The child is now dependent on technology -an increased population has grown quantitatively and now demands specialised treatments and services (Moreira & Goldani, 2010).…”

Section: Chronic Disease In Childhoodmentioning

confidence: 99%

See 1 more Smart Citation

Infantile Hospitalisation and Chronic Disease

Alves¹,

Mitre²

2012

Complementary Pediatrics

View full text Add to dashboard Cite

A criança é o pai do homem: novos desafios para a área de saúde da criança

Abstract: A criança é o pai do homem: novos desafios para a área de saúde da criançaChild is the father of man: new challenges for child health

Cited by 42 publications

References 15 publications

Neonatal near miss and mortality: factors associated with life-threatening conditions in newborns at six public maternity hospitals in Southeast Brazil

Neonatal near miss and mortality: factors associated with life-threatening conditions in newborns at six public maternity hospitals in Southeast Brazil

Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil

Infantile Hospitalisation and Chronic Disease

Contact Info

Product

Resources

About